Search for: "Watson Laboratories Inc" Results 81 - 100 of 140
Sorted by Relevance | Sort by Date
RSS Subscribe: 20 results | 100 results
17 Jul 2014, 10:58 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco Pharmaceutical Laboratories, Ltd.; Sun Pharma Global… [read post]
30 Jun 2014, 10:28 am
Reddy's Laboratories, Inc.; Glenmark Generics Inc., USA; Glenmark Generics Ltd.; Glenmark Pharmaceuticals Ltd.; Hetero USA Inc.; Hetero Labs Limited; Hetero Labs Limited Unit V; Hetero Drugs Ltd.; Mylan Pharmaceuticals Inc.; Mylan Inc.; Mylan Laboratories Limited; Par Pharmaceutical Companies, Inc.; Par Pharmaceutical, Inc.; Sun Pharma Global FZE; Caraco Pharmaceutical Laboratories, Ltd.; Sun Pharma Global… [read post]
8 Jul 2016, 2:54 am
In Thermo LabSystems [TTABlogged here], the TTAB found WATSON to be primarily a surname for laboratory management software. [read post]
18 Apr 2016, 12:49 pm by Gene Quinn
The FTC’s complaint alleges that Endo engaged in a pay for delay scheme by paying the first generic companies that filed for FDA approval – Impax Laboratories, Inc. and Watson Laboratories, Inc. [read post]
22 Feb 2017, 7:44 am by Gene Quinn
The FTC’s complaint identifies an anti-competitive reverse-payment agreement between Endo and Watson Laboratories, Inc. of Corona, CA, a company which was poised to introduce a generic version of Endo’s Lidoderm lidocaine patch into the U.S. market by the middle of 2012. [read post]
24 Mar 2009, 12:02 am
The recalled tablets were manufactured by Watson Laboratories, Inc. [read post]
14 Nov 2016, 9:16 am by Dennis Crouch
Watson Laboratories, Inc., No. 16-493 (pre-AIA, do secret sales count as prior art?) [read post]
18 Jul 2011, 5:16 pm by FDABlog HPM
(“Cephalon”) on March 15, 2011 challenging FDA’s January 7, 2011 approval of Watson Laboratories, Inc.’s (“Watson’s”) ANDA No. 079075 for a generic version of FENTORA (fentanyl) buccal tablets (approved under NDA No. 021947).  [read post]
1 Dec 2011, 2:02 pm by Tom Lamb
(NYSE: WPI) today announced that its subsidiary, Watson Laboratories, Inc., has received approval from the United States Food and Drug Administration for its Abbreviated New Drug Application for Vestura(TM) (3 mg drospirenone and 0.02 mg ethinyl estradiol), a generic version of Bayer's Yaz(R) oral contraceptive product. [read post]
25 Apr 2012, 9:05 am by FDABlog HPM
The owners of the three approved ANDAs for generic oral vancomycin—Akorn, Incorporated (“Akorn”), Watson Laboratories, Inc. [read post]
9 Nov 2007, 4:44 am
See, e.g., the Board's 2004 decision in favor of registrability of MOSCONI for billiard equipment (TTABlogged here), and this year's refusal of WATSON for laboratory software (here).Text Copyright John L. [read post]